

AVI BIOPHARMA INC
Form 8-K
October 29, 2003

[QuickLinks](#) -- Click here to rapidly navigate through this document

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): **October 29, 2003**

AVI BioPharma, Inc.

(Exact name of registrant as specified in its charter)

Oregon
(State or other jurisdiction
of incorporation or organization)

0-22613
(Commission
File No.)

93-0797222
(IRS Employer
Identification No.)

One S.W. Columbia, Suite 1105, Portland, OR 97258

(Address of principal executive offices and zip code)

Registrant's telephone number, including area code: **(503) 227-0554**

Item 5. Other Events.

On October 29, 2003, AVI BioPharma, Inc., an Oregon corporation ("the Company") ("Nasdaq") issued a press release updating progress on its infectious disease program, which uses the Company's NeuGene® antisense technology to combat single stranded RNA viruses, including the West Nile Virus (WNV), the Severe Acute Respiratory Syndrome (SARS), the Norovirus (Norwalk Virus)/Calicivirus and Hepatitis C.

A copy of the press release issued by the Company on October 29, 2003 updating the progress on its infectious disease program is attached as Exhibit 99.1 hereto and is incorporated herein by reference.

Item 7. Financial Statements, Pro Forma Financial Information and Exhibits.

(C) EXHIBITS.

**Exhibit
No.**

Description of Exhibit
